Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Dermatologic 1

Conditions

Lymphoma 15Breast Neoplasms 13Leukemia, Myeloid, Acute 11Carcinoma, Non-Small-Cell Lung 11Glioblastoma 10Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Follicular 8Brain Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Mantle-Cell 7Leukemia 7Multiple Myeloma 6Hodgkin Disease 6Neoplasms 5Myelodysplastic Syndromes 5Lymphoma, T-Cell, Cutaneous 5Lung Neoplasms 5Gliosarcoma 5Congenital Abnormalities 5Breast Neoplasms, Male 5Recurrence 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia, Erythroblastic, Acute 4Immunoblastic Lymphadenopathy 4

Interventions

blinatumomab 6Cyclophosphamide 5Rituximab 4Tacrolimus 3ponatinib 2fludarabine 2denileukin diftitox 2Vorinostat 2Vincristine 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Everolimus 2Etoposide 2Doxorubicin 2Darbepoetin alfa 2Cytarabine 2Busulfan 2Brentuximab Vedotin 2Antilymphocyte Serum 2Alemtuzumab 2tetulomab tetraxetan lu-177 1ruxolitinib 1pembrolizumab 1pegaspargase 1ibrutinib 1ibritumomab tiuxetan 1fludarabine phosphate 1ferrous sulfate 1ferric gluconate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Lymphoproliferative Disorders × Vorinostat × Clear all
NCT03713320 2022-04-08

SOLAR

miRagen Therapeutics, Inc.

Phase 2 Terminated
37 enrolled 23 charts
DermatologicLymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Mycosis Fungoides, Neoplasms, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT00773747 2021-04-30

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

Merck Sharp & Dohme LLC

Phase 3 Completed
637 enrolled 15 charts
LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡